Hepatitis C

First prospective study of direct-acting antiviral treatment of HCV in cancer patients finds that it is safe, efficacious, and that it can open options for chemotherapy.

Researchers calculate universal HCV screening of pregnant women would be cost-effective in the US, including in states with low HCV prevalence.

Analysis of multiple studies demonstrates glecaprevir/pibrentasvir pangenotypic HCV efficacy despite concurrent gastric acid-reducing drugs.

Direct-acting antiviral treatment of HCV prior to liver transplant does not increase pre-transplant liver cancer progression or post-transplant recurrence.

The first prospective, longitudinal study of direct-acting antivirals for HCV finds that treatment reduces risks of all-cause mortality and liver cancer.

A novel method to inactivate HCV in donor lungs could allow additional transplants without post-transplant antiviral treatment.

Successful HCV treatment with direct-acting antivirals provides long-term efficacy in resolving HCV-associated cryoglobulinemia vasculitis.

Hepatitis B virus may also accelerate the progression of the optical disease, according to investigators.

Sustained virologic response was achieved regardless of the hepatitis C genotype.

Universal screening for HCV infection is projected to be cost effective and provide greater benefit than the currently recommended birth cohort screening.

Reformulation of OxyContin to prevent it being dissolved and injected prompted switching to heroin and a surge in hepatitis C infections.

Despite virologic cures of hepatitis C with direct-acting antivirals, post-cure care is necessary to prevent liver disease progression and manage complications.

New host-targeting agents might help to overcome challenges in treating hepatitis C that remain, despite success with direct-acting antivirals.

Investigators are now interested in assessing potential benefits of direct-acting antivirals for HCV patients who previously had liver cancer.

Three newly discovered strains of HCV genotype 7 in Africa, and a genotype 8 in India, complicate the World Health Organization's goal to eradicate HCV.

Novel epidemiological approach accounting for persons with undiagnosed HCV shows half of cases in US are in 9 states, including 5 in Appalachia.

Mapping techniques for tracking sexually transmitted bacterial disease can also identify core areas of HCV infection to guide treatment interventions.

A series of recently presented studies support the notion of treating hepatitis C in patients already on opioid substitution therapy.

Analysis of data from phase 2 and 3 trials supports an HCV genotype 3 indication for glecaprevir/pibrentasvir, and confirms its efficacy over 8 weeks.

Sustained virological response with the treatment of HCV infection is associated with reduced mortality from extrahepatic complications, accoridng to a new study.

A large Asian population study supports the link between HCV and parkinsonism in that region, and associated treating HCV with reduced risk.

Researchers studied patients with hepatitis C in order to find out the relationship between immune activation and chronic fatigue.

Regardless of the number of previous treatment failures or emergence of the single or double RAVs after the first treatment failure all patients achieved SVR at 12 weeks on the regimen.

New research shows the majority of young people get HCV through drug use, but also finds liver disease progresses at the same pace regardless of age at diagnosis.

Investigators also found that opiate agonist therapy could have a positive effect in limiting reinfection rates after patients achieve SVR.